Hints and tips:
Related Special Reports
...“They can go to [the] website, they can get the information they need, they can be linked to a prescriber and then a pharmacy, and do all those things independent of a primary care provider.”...
...But last week Entain’s interim chief executive Stella David highlighted the strong performance of Entain CEE, through which the group owns SuperSport and STS....
...WPP’s Ogilvy advertising agency is creating a division specialising in online “health influencers” to help pharmaceutical companies tap a trend towards personalised health and combat misinformation....
...GIC took a 25 per cent stake in CitizenM five years ago in a deal that valued the business at €2bn including debt....
...A long-awaited approval decision on Moderna’s second commercial product after its Covid-19 jab has been delayed by several weeks, the US biotech said on Friday....
...“Certainly, there’s a labelling issue there that the FDA will be interested in: who has PTSD that matches what the therapy is approved for,” said David Rind, ICER’s chief medical officer....
...The first mental health treatment using schedule-1 drug MDMA faces a significant regulatory hurdle as the US Food and Drug Administration is poised to ask outside experts to scrutinise the treatment for...
...Eli Lilly’s chief executive David Ricks attributed the drugmaker’s performance to “strong sales of Mounjaro and Zepbound”, and said the company was “rapidly expanding manufacturing capacity to make our incretin...
...Novavax’s US-listed shares were trading at $10.31 before the New York open, a rise of more than 130 per cent, giving it a market value of about $1.4bn....
...The vaccine maker has undertaken a $1.1bn cost-cutting drive in the past year to stave off a possible bankruptcy and has faced pressure from an activist investor for a board shake-up....
...“That’s what we do as a leadership team . . . is ensuring that we have back-up supply if there are any issues, regardless if it’s a regulatory issue or if it’s a natural disaster or if it’s some sort of...
...UnitedHeath’s chief executive has told a US Senate committee that he is “deeply sorry” for the impact of a massive cyberattack that continues to roil the company’s Change Healthcare division....
...The antitrust regulator wrote to 10 pharmaceutical manufacturers to inform them the agency had disputed their patents with the Food and Drug Administration, giving the companies a 30-day window to respond...
...The first bankruptcy case was dismissed for a similar reason. J&J announced plans for a third attempt at a bankruptcy process last October....
...If patients live longer, “it’s good for business”, says David Altshuler, Vertex’s chief scientific officer....
...The health insurer said it recorded a net loss of around $1.53 a share in the three months to the end of March, compared with a profit of $5.95 a share during the same period last year....
...Biogen posted higher than expected profits in the first quarter as a $1bn cost-cutting drive began to pay off, but sales of its novel Alzheimer’s drug Leqembi lagged behind expectations....
...Joe Biden’s administration is planning to reclassify cannabis as a less harmful drug with a smaller legal penalty, in a historic shift for US drug policy, said people familiar with the matter....
...J&J is seeking a “pre-packaged” bankruptcy, allowing the company to expedite the Chapter 11 process if 75 per cent of plaintiffs back the move....
...Bradway added that the company was actively planning a late-stage trial for the drug, and was working to ramp up manufacturing capacity....
...Tirzepatide is part of a new class of weight-loss drugs, known as GLP-1s, which includes Novo Nordisk’s Wegovy and Ozempic drugs, that are projected to expand to a $100bn market by the end of the decade,...
...“This is a difficult decision, and like others, the challenging reimbursement environment and escalating operating costs create a lack of profitability that make the care business unsustainable for us at...
...Pfizer is gearing up to launch its first-ever gene therapy at a list price of $3.5mn, after US regulators approved the treatment for a rare blood clotting disorder on Friday....
...Eli Lilly’s weight-loss drug tirzepatide significantly reduced sleep apnoea problems in a late-stage clinical trial, the pharmaceutical group said on Wednesday, adding to evidence that could encourage more...
International Edition